Market Overview

UPDATE: JP Morgan Initiates Infinity Pharmaceuticals at Overweight on Positive Data

Related INFI
3 Small-Cap Biotechs That Institutions Are Loving
UPDATE: Morgan Stanley Initiates Coverage On Infinity Pharmaceuticals On Data Upside Driver

JP Morgan initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $42.00 price target.

JP Morgan commented, "We are initiating coverage of Infinity Pharmaceuticals with an Overweight rating based on the potential of IPI-145, the company's wholly owned, possibly best-in-class oral drug candidate for the treatment of hematologic (blood) cancers, which we believe is a billion-dollar-plus opportunity. In our view, 2013 is shaping up as another event-driven year for INFI. The stock has had an impressive run, we believe based on promising early data and recent market precedent (set by PCYC in particular)."

Infinity Pharmaceuticals closed at $33.37 on Wednesday.

Posted-In: JP MorganAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (INFI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters